Moleculomics, based at Swansea University Medical School,
has been awarded funding from Innovate UK – the UK’s innovation agency, for
technology development to find drug treatments for Covid-19 and other viral
threats. The new in silico platform, GRASP – Generic Rapid Antiviral
Screening Platform, will seek to get ahead of emerging strains of the virus by
simulating the effects of mutations before they happen,
A spin out company of the Institute of Life Science at Swansea University has recently delivered an in silico drug discovery software platform for the UK Ministry of Defence.
The software tool named TargetPath, developed for the identification of protein antibiotic or anti-bacterial target(s) within a pathogen, will be used by the scientists of Defence,
Getting better drugs to market faster, and at a fraction of the cost, is a step closer thanks to technology for speeding up the testing process, which is being developed by a Swansea University spin-out company, Moleculomics.
The company has been developing comprehensive platforms of computer-generated models for protein structures in the human body.
The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.
During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts.
Moleculomics were proud to sponsor the 2016 British Science Festival, hosted by Swansea University this year.
The British Science Festival is Europe’s longest-standing national event which connects people with scientists, engineers, technologists and social scientists. Organised by the British Science Association (BSA), the event was first held in York in 1831 and then annually at cities across the UK.
Moleculomics founder and CEO Dr Jonathan Mullins was proud to be invited as keynote speaker at the International conference on Clinical Sciences and Drug Discovery (CSDD-2016) in Dundee earlier this year.
Highly aligned to the evolution of Moleculomics, the focus of CSDD-2016 lies in the translation of academic research findings into industry-driven drug development.
Moleculomics, a company who specialise in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel therapies to meet the UK’s current and future defence and security needs.
Montreal, Canada, March 3, 2016 – Moleculomics, a UK university spin-out company offering powerful high-throughput prediction of small molecule – protein interactions using cutting-edge in silico modelling and screening tools, is pleased to announce the official opening of its North American sales and support office within the NEOMED Institute in Laval,
We recently presented a poster at the 2nd Annual Drug Discovery USA Congress, 29-30 October 2015, Boston, USA. You can view the poster below and you can then use the left and right arrow keys on your keyboard to progress through the presentation and view the poster.
Alternatively, you may download the poster in pdf format using the following link
Moleculomics, a company specializing in molecular research for the pharmaceutical, defence and biotech industries, announced the opening of its first North American facility in Greater Montréal.
Founded just four years ago in Wales, the U.K.-based company develops computing biosimulation (in silico modelling) tools and data platforms to improve knowledge of molecular interactions in new drugs and chemical compounds.